- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00231192
Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes
Study Overview
Detailed Description
This study will test the hypothesis that oral repaglinide is equivalent to insulin in the treatment of new-onset CFRD. This hypothesis will be tested using the following aims:
Specific Aim 1: To determine the effect of three months of repaglinide and insulin treatment upon blood glucose (BG) and insulin excursion during an oral glucose tolerance test.
Specific Aim 2: To determine the effect of three months of repaglinide and insulin treatment upon BG as measured by continuous glucose monitoring, fasting BG, 2-hour post-prandial BG, hemoglobin A1C, and serum fructosamine.
Secondary Aim 1: To determine the effect of three months of repaglinide and insulin treatment upon weight, body mass index, and lean body mass in adolescents with new-onset CFRD.
Secondary Aim 2: To determine the effect of three months of repaglinide and insulin treatment upon pulmonary function in adolescents with new-onset CFRD.
Secondary Aim 3: To determine the effect of three months of repaglinide and insulin treatment upon quality of life in new-onset CFRD.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4399
- The Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Cystic Fibrosis, Blood glucose concerning for diabetes -
Exclusion Criteria:
Known Cystic Fibrosis-Related Diabetes, Liver Disease, FEV1<40%
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
fasting blood glucose
|
blood glucose
|
insulin excursion during oral glucose tolerance test
|
2-hour post-prandial blood glucose
|
hemoglobin A1C
|
serum fructosamine
|
Secondary Outcome Measures
Outcome Measure |
---|
quality of life
|
weight
|
body mass index
|
lean body mass
|
pulmonary function
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Endocrine System Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Pancreatic Diseases
- Fibrosis
- Diabetes Mellitus
- Cystic Fibrosis
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Repaglinide
Other Study ID Numbers
- 2005-8-4323
- Cystic Fibrosis Foundation
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
-
University of ReadingCompletedDiabetes, Type 2 | Diabetes Mellitus, Noninsulin-DependentUnited Kingdom, Kuwait
Clinical Trials on Repaglinide and Insulin
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesMalaysia, South Africa, Hong Kong, Taiwan, Philippines
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesChina
-
Novo Nordisk A/STerminatedDiabetes Mellitus, Type 2 | DiabetesGreece
-
University of PalermoCompleted
-
Steno Diabetes Center CopenhagenCompletedDiabetes Mellitus, Type 2Denmark
-
National Institute of Diabetes and Digestive and...Novo Nordisk A/S; Cystic Fibrosis FoundationCompletedDiabetes Mellitus | Cystic FibrosisUnited States, Canada
-
Mukoviszidose Institut gGmbHAssistance Publique - Hôpitaux de Paris; Novo Nordisk A/S; Mucoviscidose-ABCF2CompletedDiabetes Mellitus | Cystic FibrosisGermany, Austria, France, Italy
-
Dalim BioTech Co., Ltd.CompletedDiabetes Mellitus, Type 2Korea, Republic of
-
Norwegian University of Science and TechnologyCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States